TY - JOUR
T1 - Treating Heparin-lnduced Thrombocytopenia in Patients Undergoing HeartMate 3 Left Ventricular Assist Device Implantation
AU - Eisenberger, Jonathan
AU - Somer, Shmuel
AU - Ram, Eilon
AU - Nachum, Eyal
AU - Frogal, Jonathan
AU - Levin, Shany
AU - Lavee, Jacob
AU - Sternik, Leonid
AU - Morgan, Jeffrey
N1 - Publisher Copyright:
© 2023 Israel Medical Association. All rights reserved.
PY - 2023
Y1 - 2023
N2 - Background: Unfractionated heparin is the preferred anticoagulant used during open heart surgeries, including left ventricular assist device (LVAD) implantation. In cases in which patients are heparin-induced thrombocytopenia positive (HIT+), the accepted practice has been to substitute heparin with bivalirudin. This practice may be associated with significant bleeding and adverse outcomes. Objectives: To review our experience with HIT+ patients who were heparin-induced thrombocytopenia with thrombosis negative (HITT-) and who underwent HeartMate 3 LVAD implantation using heparin intraoperatively rather than bivalirudin. Methods: From 2016 to 2022,1 44 adult patients were implanted with HeartMate 3 LVAD at our center. Among them, seven were detected as HIT+ but HITT- and therefore were prescribed intraoperatively with heparin and treated pre- and postoperatively with bivalirudin. We reviewed the preoperative, intraoperative, and postoperative characteristics as well as short-term mortality and the complication rates of these HIT+ patients. Results: The median age of our cohort was 56 years (51-60), 71% were male (n=5), all were INTERMACS Level 1, and most were bridged to transplant (n=6, 86%). The 30-day mortality rate post-implantation was 0%. The average 24-hour chest drain postoperative output was 1502.86 ± 931.34 ml. There were no intraoperative pump thromboses, perioperative thromboses, cerebrovascular accidents, or gastrointestinal bleeding within the first 24 hours postoperative. One patient required a revision due to bleeding. Conclusions: Intraoperative unfractionated heparin may be administered to patients who are HIT+ and HITT- while undergoing LVAD implantation. However, further investigation is required.
AB - Background: Unfractionated heparin is the preferred anticoagulant used during open heart surgeries, including left ventricular assist device (LVAD) implantation. In cases in which patients are heparin-induced thrombocytopenia positive (HIT+), the accepted practice has been to substitute heparin with bivalirudin. This practice may be associated with significant bleeding and adverse outcomes. Objectives: To review our experience with HIT+ patients who were heparin-induced thrombocytopenia with thrombosis negative (HITT-) and who underwent HeartMate 3 LVAD implantation using heparin intraoperatively rather than bivalirudin. Methods: From 2016 to 2022,1 44 adult patients were implanted with HeartMate 3 LVAD at our center. Among them, seven were detected as HIT+ but HITT- and therefore were prescribed intraoperatively with heparin and treated pre- and postoperatively with bivalirudin. We reviewed the preoperative, intraoperative, and postoperative characteristics as well as short-term mortality and the complication rates of these HIT+ patients. Results: The median age of our cohort was 56 years (51-60), 71% were male (n=5), all were INTERMACS Level 1, and most were bridged to transplant (n=6, 86%). The 30-day mortality rate post-implantation was 0%. The average 24-hour chest drain postoperative output was 1502.86 ± 931.34 ml. There were no intraoperative pump thromboses, perioperative thromboses, cerebrovascular accidents, or gastrointestinal bleeding within the first 24 hours postoperative. One patient required a revision due to bleeding. Conclusions: Intraoperative unfractionated heparin may be administered to patients who are HIT+ and HITT- while undergoing LVAD implantation. However, further investigation is required.
KW - cardiopulmonary bypass (CPB)
KW - heparin-induced thrombocytopenia (HIT)
KW - heparin-induced thrombocytopenia with thrombosis (HITT)
KW - left ventricular assist device (LVAD)
KW - platelet factor 4 (PF4)
UR - http://www.scopus.com/inward/record.url?scp=85177988009&partnerID=8YFLogxK
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 37980622
AN - SCOPUS:85177988009
SN - 1565-1088
VL - 25
SP - 757
EP - 759
JO - Israel Medical Association Journal
JF - Israel Medical Association Journal
IS - 11
ER -